Bulletin
Investor Alert

New York Markets Close in:

ADC Therapeutics S.A.

NYS: ADCT

GO
/marketstate/country/us

Countdown to close

 --Real time quotes

Jan 25, 2022, 3:38 p.m.

/zigman2/quotes/214411413/composite

$

16.58

Change

+1.13 +7.31%

Volume

Volume 166,449

Real time quotes

/zigman2/quotes/214411413/composite

Previous close

$ 15.45

$ 16.58

Change

+1.13 +7.31%

Day low

Day high

$15.35

$16.58

Open

52 week low

52 week high

$13.34

$34.48

Open

Company Description

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, ca...

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Valuation

Price to Book Ratio

7.32

Enterprise Value to EBITDA

-3.98

Enterprise Value to Sales

50.94

Total Debt to Enterprise Value

0.07

Efficiency

Income Per Employee

-1,184,087.00

Liquidity

Current Ratio

11.14

Quick Ratio

11.14

Cash Ratio

10.86

Profitability

Return on Assets

-75.62

Return on Equity

-110.28

Return on Total Capital

-77.09

Return on Invested Capital

-87.80

Capital Structure

Total Debt to Total Equity

34.30

Total Debt to Total Capital

25.54

Total Debt to Total Assets

22.40

Long-Term Debt to Equity

32.92

Long-Term Debt to Total Capital

24.51

Officers and Executives

Name Age Officer Since Title
Mr. Ron Squarer 53 2020 Chairman
Dr. Christopher John Martin 61 2011 Director & Collaboration Manager
Ms. Jennifer Creel 49 2020 Chief Financial Officer
Dr. Joseph S. Camardo 64 - Head-Medical Affairs
Dr. Patrick van Berkel 51 2012 Senior Vice President-Research & Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/adct

MarketWatch News on ADCT

  1. ADC Therapeutics started at hold with $42 stock price target at Stifel Nicolaus

    8:00 a.m. Dec. 3, 2020

    - Tomi Kilgore

  2. ADC Therapeutics stock soars 56% in trading debut

    11:05 a.m. May 15, 2020

    - Ciara Linnane

  3. ADC Therapeutics stock soars 52% in trading debut

    11:02 a.m. May 15, 2020

    - Ciara Linnane

  4. ADC Therapeutics sets IPO terms to raise up to $185.3 million

    5:48 a.m. May 14, 2020

    - Tomi Kilgore

  5. ADC Therapeutics sets IPO terms, to offer 8.1 mln shares priced at $23 to $26 each

    6:13 a.m. Sept. 23, 2019

    - Ciara Linnane

/news/nonmarketwatch/company/us/adct

Other News on ADCT

  1. Tracking Baker Brothers Portfolio - Q3 2021 Update

    10:32 p.m. Jan. 4, 2022

    - Seeking Alpha

  2. EMA validates ADC Therapeutics' lymphoma treatment Zynlonta MAA

    6:28 a.m. Oct. 29, 2021

    - Seeking Alpha

  3. Tracking Baker Brothers Portfolio - Q2 2021 Update

    11:54 p.m. Oct. 4, 2021

    - Seeking Alpha

  4. ADC Therapeutics (ADCT) Investor Presentation

    2:44 p.m. Oct. 1, 2021

    - Seeking Alpha

  5. Tracking Baker Brothers Portfolio - Q1 2021 Update

    6:50 a.m. July 8, 2021

    - Seeking Alpha

  6. Loading more headlines...

At a Glance

ADC Therapeutics SA

Biopole

Route de la Corniche 3B

Epalinges, Vaud 1066

Phone

41 2126530200

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

N/A

Net Income

$-246.29M

Employees

208.00

/news/pressrelease/company/us/adct

Press Releases on ADCT

  1. XLB, NIFE: Big ETF Outflows

    9:58 a.m. Oct. 18, 2021

    - MarketNewsVideo.com

  2. ADC Therapeutics Announces Medical Leadership Transition

    6:15 a.m. Sept. 3, 2021

    - BusinessWire - BZX

  3. Loading more headlines...
Link to MarketWatch's Slice.